Science Virometix Secures $15 Million to Advance Synthetic Vaccine Development Virometix AG, a clinical-stage biotechnology company based in Schlieren, Switzerland, has successfully completed a financing round totaling $15 million from existing shareholders. This funding... Editorial2 hours ago